Company / Revenue
Gilead Sciences Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$29.4B
FY2025
5-year range
$22.4B / $29.4B
FY2021-FY2025
Trend
+2.4%
vs FY2024
Sector context
#9 of 155
Health Care
What the data says
Among 155 Health Care companies, Gilead Sciences is in the top 6% for revenue. Revenue has increased for 4 consecutive years, from $22.4B in FY2021 to $29.4B in FY2025.
Based on SEC 10-K filings.
$29.4B in FY2025 with a 5-year CAGR of +3.6%. Top quartile in the Health Care sector.
Improved from $27.3B to $29.4B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +6.0%
- 5-Year CAGR
- +3.6%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 155This company $29.4B Sector average $4.5B
▼
+558.6% above sector average
Key checks
Key Insights
- Gilead Sciences's revenue has grown for 4 consecutive years.
- 5-year CAGR of +3.6%, indicating consistent growth.
- In FY2025, revenue increased 2.4% year-over-year.
- Ranks #9 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $29.4B | +2.4% |
| FY2024 | $28.8B | +5.3% |
| FY2023 | $27.3B | +10.6% |
| FY2022 | $24.7B | +10.0% |
| FY2021 | $22.4B | -9.1% |
| FY2020 | $24.7B | -5.4% |
| FY2019 | $26.1B | -14.1% |
| FY2018 | $30.4B | -6.9% |
| FY2017 | $32.6B | +31.1% |
| FY2016 | $24.9B | -23.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026